LOW-DOSE METHOTREXATE KINETICS IN ARTHRITIS

被引：83

作者：

EDELMAN, J

BIGGS, DF

JAMALI, F

RUSSELL, AS

机构：

[1] UNIV ALBERTA,FAC MED,DIV RHEUMATOL,EDMONTON T6G 2E1,ALBERTA,CANADA

[2] UNIV ALBERTA,FAC PHARM & PHARMACEUT SCI,EDMONTON T6G 2E1,ALBERTA,CANADA

来源：

关键词：

D O I：

10.1038/clpt.1984.47

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：382 / 386

页数：5

共 22 条

[1] PHARMACOKINETICS OF METHOTREXATE
AZARNOFF, DL
WAN, SH
HUFFMAN, DH
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1974, 16 (05) : 884 - 885
[2] METHOTREXATE - CLINICAL PHARMACOLOGY, CURRENT STATUS AND THERAPEUTIC GUIDELINES
BLEYER, WA
[J]. CANCER TREATMENT REVIEWS, 1977, 4 (02) : 87 - 101
[3] THRESHOLD METHOTREXATE CONCENTRATION FOR IN-VIVO INHIBITION OF DNA-SYNTHESIS IN NORMAL AND TUMOROUS TARGET TISSUES
CHABNER, BA
YOUNG, RC
[J]. JOURNAL OF CLINICAL INVESTIGATION, 1973, 52 (08) : 1804 - 1811
[4] DISPOSITION OF INTERMEDIATE-DOSE METHOTREXATE IN CHILDREN WITH ACUTE LYMPHOCYTIC-LEUKEMIA
EVANS, WE
STEWART, CF
HUTSON, PR
CAIRNES, DA
BOWMAN, WP
YEE, GC
CROM, WR
[J]. DRUG INTELLIGENCE & CLINICAL PHARMACY, 1982, 16 (11): : 839 - 842
[5] FREEMANNARROD M, 1975, CANCER, V36, P1619, DOI 10.1002/1097-0142(197511)36:5<1619::AID-CNCR2820360514>3.0.CO
[6] 2-G
[7] GIBALDI M, 1975, PHARMACOKINETICS
[8] HUFFMAN DH, 1973, CLIN PHARMACOL THER, V14, P572
[9] PHARMACOKINETICS OF METHOTREXATE ADMINISTERED VIA THE HEPATIC-ARTERY
IGNOFFO, RJ
OIE, S
FRIEDMAN, MA
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1981, 5 (04) : 217 - 220
[10] LEME PR, 1975, CANCER CHEMOTH REP 1, V59, P811